非阿片止痛药开发商Latigo(LTGO.US)欲乘生物科技IPO“东风”!发行定价18美元/股 拟筹资3.46亿美元

智通财经
Aug 07
【非阿片止痛药开发商Latigo(LTGO.US)欲乘生物科技IPO“东风”!发行定价18美元/股 拟筹资3.46亿美元】智通财经APP获悉,专注于开发非阿片类急性及慢性疼痛疗法、目前已接近进入三期临床阶段的生物科技公司Latigo Biotherapeutics将其美国首次公开募股(IPO)定价为每股18美元,位于此前公布的16-18美元发行价指导区间的高端。该公司计划发行1920万股股票(最终发行规模较原计划增加了27%),以筹资3.46亿美元。该公司计划在纳斯达克上市,股票代码为“LTGO”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10